Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Merrimack Pharma

- PMLiVE

Biotech challenging big pharma for M&A deals

Purchasing power growth of 'big biotech' outpaces pharma sector

- PMLiVE

Nexavar shows promise in thyroid cancer

Potential new indication for Bayer/Onyx drug

- PMLiVE

Fred Powell joins Celator as chief financial officer

Joins oncology specialist from OraPharma

- PMLiVE

Celgene signs $500m antibody deal with Sutro

Joins list of companies with interest in antibody-drug conjugates

- PMLiVE

Early FDA approval for Ariad’s leukaemia drug Iclusig

Available in US three months ahead of schedule

- PMLiVE

Roche’s Perjeta backed in EU for breast cancer

CHMP recommends use alongside Herceptin

- PMLiVE

Gilead expands in cancer with $510m YM BioSciences deal

Lands JAK inhibitor CYT387

- PMLiVE

Andrew Gengos joins ImmunoCellular as CEO

Will lead company as it initiates phase II trials investigating brain tumour vaccine

- PMLiVE

FDA approves Exelixis’ Cometriq for rare thyroid cancer

Genomics-based discovery company also submits the drug to EU regulators

Charles Morris appointed chief development officer at ImmunoGen

Previously worked in oncology for Allos, Cephalon and AstraZeneca

Eisai: Bucking the trend with R&D growth

PME’s emerging companies series continues with a firm that’s committed to research as it expands its commercial position

US HHS secretary Sebelius subpoenaed over health reform promotion

House Republicans demand investigation into Affordable Care Act PR

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links